Creo Medical Group Adjusts Valuation Amidst Management Efficiency Challenges and Rising Costs

Creo Medical Group Plc, a microcap player in the Pharmaceuticals & Biotechnology sector, has recently undergone an adjustment in evaluation. This revision reflects a shift in the company's valuation metrics, indicating a transition from a previously perceived expensive status to a more balanced fair valuation. Key financial indicators reveal a P/E ratio of 13, suggesting a competitive positioning within its industry. The Price to Book Value stands at 0.97, which aligns closely with market expectations for companies in this sector. Additionally, the company's EV to Sales ratio is recorded at 2.44, while the EV to EBITDA shows a negative figure of -1.98, highlighting some complexities in its earnings relative to enterprise value. Despite these metrics, the company has faced challenges in management efficiency, evidenced by a low return on equity (ROE) of 7.55%. Furthermore, the long-term growth trajectory appears subdued, with an annual operating profit decline of 5.53% over the past five years. The recent quarter ending June 2025 showed flat financial performance, compounded by a significant year-over-year increase in raw material costs. For those interested in tracking the evolving financial landscape of Creo Medical Group Plc, further insights can be found here: Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.